Biora Therapeutics, Inc. Research and Development Expense
Biora Therapeutics, Inc. reported Research and Development Expense of $5.61 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-11-14
- Biora Therapeutics, Inc. research and development expense for the quarter ending 2024-09-30 was $5.61M, a 46.81% decline year-over-year.
- Biora Therapeutics, Inc. research and development expense for the quarter ending 2024-06-30 was $7.70M, a 28.76% increase year-over-year.
- Biora Therapeutics, Inc. research and development expense for the quarter ending 2024-03-31 was $7.00M, a 2.57% decline year-over-year.
- Biora Therapeutics, Inc. research and development expense for the quarter ending 2023-12-31 was $6.12M, a 6.09% increase year-over-year.
- Biora Therapeutics, Inc. research and development expense for fiscal 2023 was $29.84M, a 24.07% increase from fiscal 2022.
- Biora Therapeutics, Inc. research and development expense for fiscal 2022 was $24.05M, a 47.47% decline from fiscal 2021.
- Biora Therapeutics, Inc. research and development expense for fiscal 2021 was $45.78M, a 4.10% decline from fiscal 2020.
- Biora Therapeutics, Inc. research and development expense for fiscal 2020 was $47.74M, a 24.70% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|
| 2024-09-30 | $5.61M 10-Q · filed 2024-11-14 | $13.31M derived: sum of 2 quarters · filed 2024-11-14 | $20.32M 10-Q · filed 2024-11-14 | $26.44M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2024-06-30 | $7.70M 10-Q · filed 2024-08-12 | $14.71M 10-Q · filed 2024-08-12 | $20.83M derived: sum of 3 quarters · filed 2024-08-12 | $31.37M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2024-03-31 | $7.00M 10-Q · filed 2024-05-15 | $13.12M derived: sum of 2 quarters · filed 2024-05-15 | $23.67M derived: sum of 3 quarters · filed 2024-11-14 | $29.65M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-12-31 | $6.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $16.66M derived: sum of 2 quarters · filed 2024-11-14 | $22.65M derived: sum of 3 quarters · filed 2024-11-14 | $29.84M 10-K · filed 2024-04-01 | ||
| 2023-09-30 | $10.55M 10-Q · filed 2024-11-14 | $16.53M derived: sum of 2 quarters · filed 2024-11-14 | $23.72M 10-Q · filed 2024-11-14 | $29.49M derived: sum of 4 quarters · filed 2024-11-14 | ||
| 2023-06-30 | $5.98M 10-Q · filed 2024-08-12 | $13.17M 10-Q · filed 2024-08-12 | $18.94M derived: sum of 3 quarters · filed 2024-08-12 | $24.76M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | $7.19M 10-Q · filed 2024-05-15 | $12.96M derived: sum of 2 quarters · filed 2024-05-15 | $18.78M derived: sum of 3 quarters · filed 2024-05-15 | $24.68M derived: sum of 4 quarters · filed 2024-05-15 | ||
| 2022-12-31 | $5.77M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $11.59M derived: sum of 2 quarters · filed 2024-04-01 | $17.49M derived: sum of 3 quarters · filed 2024-04-01 | $24.05M 10-K · filed 2024-04-01 | ||
| 2022-09-30 | $5.82M 10-Q · filed 2023-11-13 | $11.72M derived: sum of 2 quarters · filed 2023-11-13 | $18.28M 10-Q · filed 2023-11-13 | $26.77M derived: sum of 4 quarters · filed 2023-11-13 | ||
| 2022-06-30 | $5.90M 10-Q · filed 2023-08-14 | $12.46M 10-Q · filed 2023-08-14 | $20.95M derived: sum of 3 quarters · filed 2023-08-14 | $33.17M derived: sum of 4 quarters · filed 2023-08-14 | ||
| 2022-03-31 | $6.56M 10-Q · filed 2023-05-15 | $15.04M derived: sum of 2 quarters · filed 2023-05-15 | $27.27M derived: sum of 3 quarters · filed 2023-05-15 | $40.67M derived: sum of 4 quarters · filed 2023-05-15 | ||
| 2021-12-31 | $8.48M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $20.71M derived: sum of 2 quarters · filed 2023-03-30 | $34.11M derived: sum of 3 quarters · filed 2023-03-30 | $45.78M 10-K · filed 2023-03-30 | ||
| 2021-09-30 | $12.23M 10-Q · filed 2022-11-14 | $25.63M derived: sum of 2 quarters · filed 2022-11-14 | $37.30M 10-Q · filed 2022-11-14 | $48.52M derived: sum of 4 quarters · filed 2022-11-14 | ||
| 2021-06-30 | $13.40M 10-Q · filed 2022-08-15 | $25.07M 10-Q · filed 2022-08-15 | $36.30M derived: sum of 3 quarters · filed 2022-08-15 | $49.34M derived: sum of 4 quarters · filed 2022-08-15 | ||
| 2021-03-31 | $11.67M 10-Q · filed 2022-05-10 | $22.90M derived: sum of 2 quarters · filed 2022-05-10 | $35.94M derived: sum of 3 quarters · filed 2022-05-10 | $48.17M derived: sum of 4 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $11.22M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $24.27M derived: sum of 2 quarters · filed 2022-03-28 | $36.50M derived: sum of 3 quarters · filed 2022-03-28 | $47.74M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $13.04M 10-Q · filed 2021-11-10 | $25.28M derived: sum of 2 quarters · filed 2021-11-10 | $36.52M 10-Q · filed 2021-11-10 | $36.52M 10-Q · filed 2020-11-09 | $51.13M derived: sum of 4 quarters · filed 2021-11-10 | |
| 2020-06-30 | $12.23M 10-Q · filed 2021-08-12 | $23.48M 10-Q · filed 2021-08-12 | $23.47M 10-Q · filed 2020-08-14 | $38.08M derived: sum of 3 quarters · filed 2021-08-12 | $55.16M derived: sum of 4 quarters · filed 2021-08-12 | |
| 2020-03-31 | $11.24M 10-Q · filed 2021-05-13 | $25.85M derived: sum of 2 quarters · filed 2021-05-13 | $42.93M derived: sum of 3 quarters · filed 2021-05-13 | $59.39M derived: sum of 4 quarters · filed 2021-05-13 | ||
| 2019-12-31 | $14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-18 | $31.69M derived: sum of 2 quarters · filed 2021-03-18 | $48.15M derived: sum of 3 quarters · filed 2021-03-18 | $63.40M 10-K · filed 2021-03-18 | ||
| 2019-09-30 | $17.08M 10-Q · filed 2020-11-09 | $33.54M derived: sum of 2 quarters · filed 2020-11-09 | $48.79M 10-Q · filed 2020-11-09 | |||
| 2019-06-30 | $16.46M 10-Q · filed 2020-08-14 | $31.71M 10-Q · filed 2020-08-14 |